vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v22i5.2619vsp-3298Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСовременные возможности коррекции эпидермальной дисфункции при атопическом дерматитеModern Treatment Options for Epidermal Dysfunction at Atopic Dermatitishttps://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.

Амбарчян Эдуард Тигранович - кандидат медицинских наук, заведующий отделением дерматологии.

117593, Литовский бульвар, д. 1а

Moscow

edo_amb@mail.ruhttps://orcid.org/0000-0003-3003-9398КузьминоваА. Д.KuzminovaAnastasiya D.

Moscow

https://orcid.org/0000-0002-6760-3119ИванчиковВ. В.IvanchikovVladislav V.

Moscow

НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian Federation202305112023225382386Copyright © Амбарчян Э.Т., Кузьминова А.Д., Иванчиков В.В., 20232023Амбарчян Э.Т., Кузьминова А.Д., Иванчиков В.В.Ambarchyan E.T., Kuzminova A.D., Ivanchikov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3298

Атопический дерматит (АтД) — хроническое воспалительное заболевание кожи, важным звеном патогенеза которого является нарушение эпидермального барьера. Одну из главенствующих ролей в данной проблеме занимает белок филаггрин и ассоциированные с ним мутации гена филаггрина. В настоящее время с целью более персонализированного подхода и повышения эффективности терапии у пациентов с АтД создаются и внедряются в практику новые топические средства из класса эмолентов, позволяющие восстанавливать функцию эпидермального барьера и добиваться нивелирования симптомов заболевания.

Atopic dermatitis (AD) is a chronic inflammatory skin disease. Its crucial component of pathogenesis is malfunction of the epidermal barrier. Filaggrin protein and associated mutations in the filaggrin gene play one of the key roles in this problem. Nowadays new topical products (emollients) has been created and implemented into practice with the aim of more personalized approach and increased therapy efficacy in patients with AD. Such drugs would allow us to restore epidermal barrier function and to achieve elimination of disease symptoms.

атопический дерматитфилаггринфилагринолэпидермальный барьерэмолентыatopic dermatitisfilaggrinfilagrinolepidermal barrieremollientОтсутствуетNot declaredReferencesRauer L, Reiger M, Bhattacharyya M, et al. Skin microbiome and its association with host cofactors in determining atopic dermatitis severity. J Eur Acad Dermatol Venereol. 2023;37(4):772–782. doi: https://doi.org/10.1111/jdv.18776Rauer L, Reiger M, Bhattacharyya M, et al. Skin microbiome and its association with host cofactors in determining atopic dermatitis severity. J Eur Acad Dermatol Venereol. 2023;37(4):772–782. doi: https://doi.org/10.1111/jdv.18776Boguniewicz M, Alexis AF, Beck LA, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–1531. doi: https://doi.org/10.1016/j.jaip.2017.08.005Boguniewicz M, Alexis AF, Beck LA, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–1531. doi: https://doi.org/10.1016/j.jaip.2017.08.005Taylor K, Swan DJ, Affleck A, et al. Translational Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017;176(6):1617–1623. doi: https://doi.org/10.1111/bjd.15235Taylor K, Swan DJ, Affleck A, et al. Translational Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017;176(6):1617–1623. doi: https://doi.org/10.1111/bjd.15235Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi: https://doi.org/10.1016/j.anai.2020.12.020Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi: https://doi.org/10.1016/j.anai.2020.12.020Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651. doi: https://doi.org/10.1016/j.jaci.2016.07.013Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651. doi: https://doi.org/10.1016/j.jaci.2016.07.013Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e7. doi: https://doi.org/10.1016/j.jaad.2018.05.1241Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e7. https://doi.org/10.1016/j.jaad.2018.05.1241Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–1503. doi: https://doi.org/10.1172/JCI124611Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–1503. doi: https://doi.org/10.1172/JCI124611Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840–1852. doi: https://doi.org/10.1016/j.jaip.2020.02.022Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840–1852. doi: https://doi.org/10.1016/j.jaip.2020.02.022Beck LA, Cork MJ, Amagai M, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innov. 2022;2(5):100131. doi: https://doi.org/10.1016/j.xjidi.2022.100131Beck LA, Cork MJ, Amagai M, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innov. 2022;2(5):100131. doi: https://doi.org/10.1016/j.xjidi.2022.100131Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023): 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XWeidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023): 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XBarker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127(3):564–567. doi: https://doi.org/10.1038/sj.jid.5700587Barker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127(3):564–567. doi: https://doi.org/10.1038/sj.jid.5700587Saunders SP, Moran T, Floudas A, et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol. 2016;137(2):482–491. doi: https://doi.org/10.1016/j.jaci.2015.06.045Saunders SP, Moran T, Floudas A, et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol. 2016;137(2):482–491. doi: https://doi.org/10.1016/j.jaci.2015.06.045Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022Kim BE, Leung DYM. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy Asthma Immunol Res. 2018;10(3): 207–215. doi: https://doi.org/10.4168/aair.2018.10.3.207Kim BE, Leung DYM. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy Asthma Immunol Res. 2018;10(3): 207–215. doi: https://doi.org/10.4168/aair.2018.10.3.207Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138:350–358.e1. doi: https://doi.org/10.1016/j.jaci.2016.06.002Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138:350–358.e1. doi: https://doi.org/10.1016/j.jaci.2016.06.002Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–S127. doi: https://doi.org/10.1016/j.jaci.2003.09.033Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–S127. doi: https://doi.org/10.1016/j.jaci.2003.09.033Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: https://doi.org/10.1016/j.jaci.2017.04.004Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: https://doi.org/10.1016/j.jaci.2017.04.004Grobe W, Bieber T, Novak N. Pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges. 2019;17(4):433–440. doi: https://doi.org/10.1111/ddg.13819Grobe W, Bieber T, Novak N. Pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges. 2019;17(4):433–440. doi: https://doi.org/10.1111/ddg.13819Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2020; 48(2):130–139. doi: https://doi.org/10.1111/1346-8138.15664Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2020; 48(2):130–139. doi: https://doi.org/10.1111/1346-8138.15664Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020; 21(8):2867. doi: https://doi.org/10.3390/ijms21082867Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020; 21(8):2867. doi: https://doi.org/10.3390/ijms21082867Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: A systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: A systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: The skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi: https://doi.org/10.1111/bjd.16934Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: The skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi: https://doi.org/10.1111/bjd.16934Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10): 2511–2514. doi: https://doi.org/10.1038/jid.2010.161Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10): 2511–2514. doi: https://doi.org/10.1038/jid.2010.161Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: Beyond filaggrin. Bras Dermatol. 2016;91(4):472–478. doi: https://doi.org/10.1590/abd1806-4841.20164412Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: Beyond filaggrin. Bras Dermatol. 2016;91(4):472–478. doi: https://doi.org/10.1590/abd1806-4841.20164412Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013; 131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013; 131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566Мурашкин Н.Н., Иванов Р.А., Амбарчян Э.Т. и др. Филаггрин и атопический дерматит: клинико-патогенетические параллели и возможности терапевтической коррекции // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 435–440. — doi: https://doi.org/10.15690/vsp.v20i5.2320Murashkin NN, Ivanov RA, Ambarchian ET, et al. Filaggrin and Atopic Dermatitis: Clinical and Pathogenetic Parallels and Therapeutic Possibilities. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):435–440. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2320Moosbrugger-Martinz V, Leprince C, Méchin M-C, et al. Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci. 2022;23(10):5318. doi: https://doi.org/10.3390/ijms23105318Moosbrugger-Martinz V, Leprince C, Méchin M-C, et al. Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci. 2022;23(10):5318. doi: https://doi.org/10.3390/ijms23105318On HR, Lee SE, Kim SE, et al. Filaggrin Mutation in Korean Patients with Atopic Dermatitis. Yonsei Med J. 2017;58(2): 395–400. doi: https://doi.org/10.3349/ymj.2017.58.2.395On HR, Lee SE, Kim SE, et al. Filaggrin Mutation in Korean Patients with Atopic Dermatitis. Yonsei Med J. 2017;58(2): 395–400. doi: https://doi.org/10.3349/ymj.2017.58.2.395Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1–9. doi: https://doi.org/10.2332/allergolint.10-RAI-0270Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1–9. doi: https://doi.org/10.2332/allergolint.10-RAI-0270Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: https://doi.org/10.11613/BM.2019.020501Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: https://doi.org/10.11613/BM.2019.020501Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi: https://doi.org/10.1038/jid.2011.393Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi: https://doi.org/10.1038/jid.2011.393Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta. 1982;719(1):110–117. doi: https://doi.org/10.1016/0304-4165(82)90314-2Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta. 1982;719(1):110–117. doi: https://doi.org/10.1016/0304-4165(82)90314-2Hoste E, Kemperman P, Devos M, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–2241. doi: https://doi.org/10.1038/jid.2011.153Hoste E, Kemperman P, Devos M, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–2241. doi: https://doi.org/10.1038/jid.2011.153Kamata Y, Taniguchi A, Yamamoto M, et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem. 2009;284(19):12829–12836. doi: https://doi.org/10.1074/jbc.M807908200Kamata Y, Taniguchi A, Yamamoto M, et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem. 2009;284(19):12829–12836. doi: https://doi.org/10.1074/jbc.M807908200Круглова Л.С., Переверзина Н.О. Филаггрин: от истории открытия до применения модуляторов филаггрина в клинической практике (обзор литературы) // Медицинский алфавит. — 2021. — № 27. — С. 8–12. — doi: https://doi.org/10.33667/2078-5631-2021-27-8-12Kruglova LS, Pereverzina NO. Filaggrin: from history of discovery to clinical usage (literature review). Medical alphabet. 2021;(27):8–12. (In Russ). doi: https://doi.org/10.33667/2078-5631-2021-27-8-12Мурашкин Н.Н., Епишев Р.В., Иванов Р.А. и др. Инновации в терапевтической коррекции микробиома кожи при атопическом дерматите в детском возрасте // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 352–361. — doi: https://doi.org/10.15690/vsp.v21i5.2449Murashkin NN, Epishev RV, Ivanov RA, et al. Innovations in Therapeutic Improvement of the Cutaneous Microbiome in Children with Atopic Dermatitis. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(5):352–361. (In Russ). doi: https://doi.org/10.15690/vsp.v21i5.2449Kezic S, O’Regan GM, Yau N, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy. 2011;66(7):934–940. doi: https://doi.org/10.1111/j.1398-9995.2010.02540.xKezic S, O’Regan GM, Yau N, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy. 2011;66(7):934–940. doi: https://doi.org/10.1111/j.1398-9995.2010.02540.xZeeuwen PL, Ederveen TH, Van Der Krieken DA, et al. Grampositive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skin. J Allergy Clin Immunol. 2017;139(4): 1368–1371. doi: https://doi.org/10.1016/j.jaci.2016.09.017Zeeuwen PL, Ederveen TH, Van Der Krieken DA, et al. Grampositive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skin. J Allergy Clin Immunol. 2017;139(4): 1368–1371. doi: https://doi.org/10.1016/j.jaci.2016.09.017Emmert H, Baurecht H, Thielking F, et al. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. Exp Dermatol. 2021;30(10):1398–1408. doi: https://doi.org/10.1111/exd.14185Emmert H, Baurecht H, Thielking F, et al. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. Exp Dermatol. 2021;30(10):1398–1408. doi: https://doi.org/10.1111/exd.14185Clausen ML, Agner T, Lilje B, et al. Association of Disease Severity With Skin Microbiome and Filaggrin Gene Mutations in Adult Atopic Dermatitis. JAMA Dermatol. 2018;154(3):293–300. doi: https://doi.org/10.1001/jamadermatol.2017.5440Clausen ML, Agner T, Lilje B, et al. Association of Disease Severity With Skin Microbiome and Filaggrin Gene Mutations in Adult Atopic Dermatitis. JAMA Dermatol. 2018;154(3):293–300. doi: https://doi.org/10.1001/jamadermatol.2017.5440Baurecht H, Ruhlemann MC, Rodriguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;141(1):1668–1676. doi: https://doi.org/10.1016/j.jaci.2018.01.019Baurecht H, Ruhlemann MC, Rodriguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;141(1):1668–1676. doi: https://doi.org/10.1016/j.jaci.2018.01.019Мурашкин Н.Н., Амбарчян Э.Т., Материкин А.И., Епишев Р.В. Роль нарушений эпидермального барьера при атопическом дерматите: современные концепции патогенеза заболевания // Вопросы современной педиатрии. — 2018. — Т. 17. — № 1. — С. 85–88. — doi: https://doi.org/10.15690/vsp.v17i1.1859Murashkin NN, Ambarchian ET, Materikin AI, Epishev RV. The Role of Epidermal Barrier Impairments in Atopic Dermatitis: Modern Concepts of Disease Pathogenesis. Voprosy sovremennoi pediatrii — Current Pediatrics. 2018;17(1):85–88. (In Russ). doi: https://doi.org/10.15690/vsp.v17i1.1859Feuillie C, Vitry P, McAleer MA, et al. Adhesion of Staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. mBio. 2018;9(4):e01184-18. doi: https://doi.org/10.1128/mBio.01184-18Feuillie C, Vitry P, McAleer MA, et al. Adhesion of Staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. mBio. 2018;9(4):e01184-18. doi: https://doi.org/10.1128/mBio.01184-18Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В. и др. Дефект филаггрина при атопическом дерматите: современные методы коррекции // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 347–351. — doi: https://doi.org/10.15690/vsp.v21i5.2452Murashkin NN, Opryatin LA, Epishev RV, et al. Filaggrin Defect at Atopic Dermatitis: Modern Treatment Options. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(5):347–351. (In Russ). doi: https://doi.org/10.15690/vsp.v21i5.2452Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY’S LABORATORIES LIMITED.Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY’S LABORATORIES LIMITED.Татаурщикова Н.С., Летяева О.И., Русанова А.С. Ведение пациентов с атопическим дерматитом в рутинной клинической практике // РМЖ. Медицинское обозрение. — 2022. — Т. 6. — № 2. — С. 72–78. — doi: https://doi.org/10.32364/2587-68212022-6-2-72-78Tataurshchikova NS, Letyaeva OI, Rusanova AS. Management of atopic dermatitis in routine clinical practice. Russian Medical Inquiry. 2022;6(2):72–78. (In Russ). doi: https://doi.org/10.32364/2587-6821-2022-6-2-72-78Аравийская Е.Р., Бакулев А.Л., Гаджигороева А.Г. и др. Практические вопросы применения эмолентов, содержащих модуляторы филаггрина, в ведении пациентов с атопическим дерматитом и ксерозом: резолюция Совета экспертов // Российский аллергологический журнал. — 2022. — Т. 19. — № 2. — С. 245–258. — doi: https://doi.org/10.36691/RJA1538Araviyskaya ER, Bakulev AL, Gadzhigoroeva AG, et al. Practical issues in the use of emollients containing filaggrin modulators in the management of patients with atopic dermatitis and xerosis: Resolution of the Expert board. Russian Journal of Allergy. 2022;19(2):245–258. (In Russ). doi: https://doi.org/10.36691/RJA1538

The authors declare that there are no conflicts of interest present.